Role of interleukin‐6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation
Open accessThe DOI matches its Crossref record.
Abstract
The process of cardiac hypertrophy is considered to involve two components: that of cardiac myocyte (CM) enlargement and cardiac fibroblast (CF) proliferation. The interleukin‐6 (IL‐6) family cytokines have been implicated in a variety of cellular and molecular interactions between myocytes and non‐myocytes (NCMs), which in turn have important roles in the development of cardiac hypertrophy. In the study of these interactions, we previously detected very high levels of IL‐6 in supernatants of a “dedifferentiated model” of adult ventricular CMs cultured with CFs. In the present study, we have used this in vitro coculture system to examine how IL‐6 is involved in the interactions between CMs and CFs during CM hypertrophy and CF proliferation. IL‐6 and its signal transducer, 130‐kDa glycoprotein (gp130), were detected by immunostaining cultured CMs and CFs with anti‐IL‐6 or anti‐gp130 antibodies. Addition of anti‐IL‐6 or anti‐gp130 antagonist antibodies into CM/CF cocultures induced a significant decrease in expression of atrial natriuretic peptide (ANP) and β‐myosin heavy chain (β‐MHC) in CMs. The presence of IL‐6 antagonist also resulted in a decrease in the surface area of 12‐day‐old CMs cultured with CFs or in the presence of fibroblast conditioned medium (FCM), and decreased fibroblast proliferation in CM/CF cocultures, particularly in the presence of a gp130 antagonist. The results also show that angiotensin II (AngII) is mainly secreted by CFs and induces IL‐6 secretion in CMs cultured with CFs or with FCM. In addition, the effects of IL‐6 on cardiomyocyte hypertrophy and fibroblast proliferation were inhibited by addition of the AT‐1 receptor antagonist, losartan. These results suggest that IL‐6 contributes significantly to CM hypertrophy by an autocrine pathway and to fibroblast proliferation by a paracrine pathway and that these effects could be mediated by AngII. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cardiac fibroblasts: At the heart of myocardial remodeling
Porter, K. E., & Turner, N. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.002 · Cited by 1,010
Cardiac fibroblasts: friend or foe?
Baudino, T. A., Carver, W., Giles, W., & Borg, T. K. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00023.2006 · Cited by 427
Suthahar, N., Meijers, W. C., Silljé, H. H. W., & de Boer, R. A. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0343-y · Cited by 307
“Crosstalk between fibroblasts and cardiomyocytes is also important in cardiac remodelling; myofibroblasts induce and modify cardiomyocyte hypertrophy through such mechanisms [55, 56].”
BackgroundKarnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
Resident fibroblast expansion during cardiac growth and remodeling
Ivey, M. J., Kuwabara, J. T., Pai, J. T., Moore, R. E., Sun, Z., & Tallquist, M. D. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.11.012 · Cited by 146
Castello, L., Maina, M., Testa, G., Cavallini, G., Biasi, F., Donati, A., Leonarduzzi, G., Bergamini, E., Poli, G., & Chiarpotto, E. (2011) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2011.06.006 · Cited by 34
Mwendwa, D. T., Ali, M. K., Sims, R. C., Cole, A. P., Lipscomb, M. W., Levy, S.-A., Callender, C. O., & Campbell, A. L. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.10.019 · Cited by 27
Metadata
- Authors
- Fredj, S., Bescond, J., Louault, C., Delwail, A., Lecron, J., & Potreau, D.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2005-02-16
- Volume
- 204
- Issue
- 2
- Pages
- 428-436
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2087495354
- Cited by
- 114
- References
- 0
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.